{"id":10765,"date":"2015-08-08T22:43:15","date_gmt":"2015-08-08T19:43:15","guid":{"rendered":"https:\/\/mssociety.org.il\/en\/?p=10765"},"modified":"2021-01-30T12:10:54","modified_gmt":"2021-01-30T10:10:54","slug":"2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11","status":"publish","type":"post","link":"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/","title":{"rendered":"Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11)"},"content":{"rendered":"<p><span style=\"color: #ff6600;\"><strong>Introduction<\/strong><\/span>: The BENEFIT trial demonstrated improved clinical outcomes in patients with a clinically-isolated syndrome (CIS) and early treatment with interferon beta-1b up to 11 years after randomization. Cognitive outcomes and cognitive fatigue data at Year 11 are presented here.<\/p>\n<p><span style=\"color: #ff6600;\"><strong>Conclusion<\/strong><\/span>: Superior PASAT performance in the early treatment group occurred early and persisted over 11 years. SDMT results are comparable to data from other MS populations of similar disease duration and healthy volunteers. These findings add more objective evidence that confirms the beneficial impact of early treatment with interferon beta-1b on the clinical course of MS.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Introduction: The BENEFIT trial demonstrated improved clinical outcomes in patients with a clinically-isolated syndrome (CIS) and early treatment with interferon beta-1b up to 11 years after randomization. Cognitive outcomes and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[745,384],"tags":[],"class_list":["post-10765","post","type-post","status-publish","format-standard","hentry","category-therapeutic-information-by-pharmaceutical-companies","category-articles"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11) - The Israel Multiple Sclerosis Society<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11) - The Israel Multiple Sclerosis Society\" \/>\n<meta property=\"og:description\" content=\"Introduction: The BENEFIT trial demonstrated improved clinical outcomes in patients with a clinically-isolated syndrome (CIS) and early treatment with interferon beta-1b up to 11 years after randomization. Cognitive outcomes and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/\" \/>\n<meta property=\"og:site_name\" content=\"The Israel Multiple Sclerosis Society\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/agudaims\" \/>\n<meta property=\"article:published_time\" content=\"2015-08-08T19:43:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-01-30T10:10:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mssociety.org.il\/wp-content\/uploads\/2021\/01\/mssociety-logo-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"176\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/mssociety.org.il\/en\/#\/schema\/person\/a4f88177df9bd42d818422d7d0ad4bcb\"},\"headline\":\"Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11)\",\"datePublished\":\"2015-08-08T19:43:15+00:00\",\"dateModified\":\"2021-01-30T10:10:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/\"},\"wordCount\":113,\"publisher\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/#organization\"},\"articleSection\":[\"Therapeutic information by pharmaceutical companies\",\"Articles\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/\",\"url\":\"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/\",\"name\":\"Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11) - The Israel Multiple Sclerosis Society\",\"isPartOf\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/#website\"},\"datePublished\":\"2015-08-08T19:43:15+00:00\",\"dateModified\":\"2021-01-30T10:10:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u05e8\u05d0\u05e9\u05d9\",\"item\":\"https:\/\/mssociety.org.il\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"About Multiple Sclerosis\",\"item\":\"https:\/\/mssociety.org.il\/en\/category\/about-multiple-sclerosis\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Therapeutic information by pharmaceutical companies\",\"item\":\"https:\/\/mssociety.org.il\/en\/category\/about-multiple-sclerosis\/therapeutic-information-by-pharmaceutical-companies\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mssociety.org.il\/en\/#website\",\"url\":\"https:\/\/mssociety.org.il\/en\/\",\"name\":\"The Israel Multiple Sclerosis Society\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mssociety.org.il\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mssociety.org.il\/en\/#organization\",\"name\":\"\u05d4\u05d0\u05d2\u05d5\u05d3\u05d4 \u05d4\u05d9\u05e9\u05e8\u05d0\u05dc\u05d9\u05ea \u05dc\u05d8\u05e8\u05e9\u05ea \u05e0\u05e4\u05d5\u05e6\u05d4\",\"url\":\"https:\/\/mssociety.org.il\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mssociety.org.il\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mssociety.org.il\/wp-content\/uploads\/2021\/01\/mssociety-logo-1.png\",\"contentUrl\":\"https:\/\/mssociety.org.il\/wp-content\/uploads\/2021\/01\/mssociety-logo-1.png\",\"width\":600,\"height\":176,\"caption\":\"\u05d4\u05d0\u05d2\u05d5\u05d3\u05d4 \u05d4\u05d9\u05e9\u05e8\u05d0\u05dc\u05d9\u05ea \u05dc\u05d8\u05e8\u05e9\u05ea \u05e0\u05e4\u05d5\u05e6\u05d4\"},\"image\":{\"@id\":\"https:\/\/mssociety.org.il\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/agudaims\",\"https:\/\/www.youtube.com\/channel\/UCCfPf2JEIWquD7cPkWzK9ow\/videos\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mssociety.org.il\/en\/#\/schema\/person\/a4f88177df9bd42d818422d7d0ad4bcb\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mssociety.org.il\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6a37ae243f1f421abdfa60cd5f7943a1c0dac9d5faa682525f0c3f0229cc5e2d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6a37ae243f1f421abdfa60cd5f7943a1c0dac9d5faa682525f0c3f0229cc5e2d?s=96&d=mm&r=g\",\"caption\":\"admin\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11) - The Israel Multiple Sclerosis Society","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/","og_locale":"en_US","og_type":"article","og_title":"Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11) - The Israel Multiple Sclerosis Society","og_description":"Introduction: The BENEFIT trial demonstrated improved clinical outcomes in patients with a clinically-isolated syndrome (CIS) and early treatment with interferon beta-1b up to 11 years after randomization. Cognitive outcomes and [&hellip;]","og_url":"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/","og_site_name":"The Israel Multiple Sclerosis Society","article_publisher":"https:\/\/www.facebook.com\/agudaims","article_published_time":"2015-08-08T19:43:15+00:00","article_modified_time":"2021-01-30T10:10:54+00:00","og_image":[{"width":600,"height":176,"url":"https:\/\/mssociety.org.il\/wp-content\/uploads\/2021\/01\/mssociety-logo-1.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/#article","isPartOf":{"@id":"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/"},"author":{"name":"admin","@id":"https:\/\/mssociety.org.il\/en\/#\/schema\/person\/a4f88177df9bd42d818422d7d0ad4bcb"},"headline":"Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11)","datePublished":"2015-08-08T19:43:15+00:00","dateModified":"2021-01-30T10:10:54+00:00","mainEntityOfPage":{"@id":"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/"},"wordCount":113,"publisher":{"@id":"https:\/\/mssociety.org.il\/en\/#organization"},"articleSection":["Therapeutic information by pharmaceutical companies","Articles"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/","url":"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/","name":"Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11) - The Israel Multiple Sclerosis Society","isPartOf":{"@id":"https:\/\/mssociety.org.il\/en\/#website"},"datePublished":"2015-08-08T19:43:15+00:00","dateModified":"2021-01-30T10:10:54+00:00","breadcrumb":{"@id":"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mssociety.org.il\/en\/2015-impact-of-early-treatment-of-ms-with-interferon-beta-1b-cognitive-outcomes-at-the-11-year-follow-up-of-benefit-benefit-11\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u05e8\u05d0\u05e9\u05d9","item":"https:\/\/mssociety.org.il\/en\/"},{"@type":"ListItem","position":2,"name":"About Multiple Sclerosis","item":"https:\/\/mssociety.org.il\/en\/category\/about-multiple-sclerosis\/"},{"@type":"ListItem","position":3,"name":"Therapeutic information by pharmaceutical companies","item":"https:\/\/mssociety.org.il\/en\/category\/about-multiple-sclerosis\/therapeutic-information-by-pharmaceutical-companies\/"},{"@type":"ListItem","position":4,"name":"Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11)"}]},{"@type":"WebSite","@id":"https:\/\/mssociety.org.il\/en\/#website","url":"https:\/\/mssociety.org.il\/en\/","name":"The Israel Multiple Sclerosis Society","description":"","publisher":{"@id":"https:\/\/mssociety.org.il\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mssociety.org.il\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mssociety.org.il\/en\/#organization","name":"\u05d4\u05d0\u05d2\u05d5\u05d3\u05d4 \u05d4\u05d9\u05e9\u05e8\u05d0\u05dc\u05d9\u05ea \u05dc\u05d8\u05e8\u05e9\u05ea \u05e0\u05e4\u05d5\u05e6\u05d4","url":"https:\/\/mssociety.org.il\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mssociety.org.il\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mssociety.org.il\/wp-content\/uploads\/2021\/01\/mssociety-logo-1.png","contentUrl":"https:\/\/mssociety.org.il\/wp-content\/uploads\/2021\/01\/mssociety-logo-1.png","width":600,"height":176,"caption":"\u05d4\u05d0\u05d2\u05d5\u05d3\u05d4 \u05d4\u05d9\u05e9\u05e8\u05d0\u05dc\u05d9\u05ea \u05dc\u05d8\u05e8\u05e9\u05ea \u05e0\u05e4\u05d5\u05e6\u05d4"},"image":{"@id":"https:\/\/mssociety.org.il\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/agudaims","https:\/\/www.youtube.com\/channel\/UCCfPf2JEIWquD7cPkWzK9ow\/videos"]},{"@type":"Person","@id":"https:\/\/mssociety.org.il\/en\/#\/schema\/person\/a4f88177df9bd42d818422d7d0ad4bcb","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mssociety.org.il\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6a37ae243f1f421abdfa60cd5f7943a1c0dac9d5faa682525f0c3f0229cc5e2d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6a37ae243f1f421abdfa60cd5f7943a1c0dac9d5faa682525f0c3f0229cc5e2d?s=96&d=mm&r=g","caption":"admin"}}]}},"_links":{"self":[{"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/posts\/10765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/comments?post=10765"}],"version-history":[{"count":0,"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/posts\/10765\/revisions"}],"wp:attachment":[{"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/media?parent=10765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/categories?post=10765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mssociety.org.il\/en\/wp-json\/wp\/v2\/tags?post=10765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}